Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelvo versus placebo in active lupus nephritis
NL-OMON49474Phase 3Active, not recruiting
- Sponsor
- Worldwide Clinical Trials
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Orelvo plus background therapy with Placebo plus background therapy (2 arms). Primary endpoint: Renal response at Week 52. Started Oct 2017; status: active, not recruiting.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49474.